Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It combines four medications, elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide, into a single pill. This combination is designed to inhibit the replication of HIV in the body and improve the immune system's function by reducing the viral load to undetectable levels. The use of fixed-dose combination drugs like elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide simplifies the HIV treatment regimen, improving adherence and reducing the likelihood of viral resistance.

Composition

The medication consists of the following components:

• Elvitegravir - an integrase inhibitor that blocks the HIV integrase enzyme, preventing the viral DNA from integrating into the host cell's DNA.
• Cobicistat - a pharmacoenhancer that inhibits the enzyme CYP3A4, increasing the effectiveness of elvitegravir by slowing its breakdown in the body.
• Emtricitabine - a nucleoside reverse transcriptase inhibitor (NRTI) that interferes with the reverse transcriptase enzyme, stopping the virus from making copies of itself.
• Tenofovir alafenamide - a prodrug of tenofovir, another NRTI, which is converted into its active form inside the body, providing effective drug levels with lower doses and potentially fewer side effects.

Indications

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) with no history of treatment failure and no known substitutions associated with resistance to the individual components of the medication.

Administration

The medication is taken orally, once daily, with food. It is important to follow the prescription exactly as directed by a healthcare provider to ensure the best possible outcome.

Side Effects

Common side effects include, but are not limited to, nausea, diarrhea, fatigue, and headache. Serious side effects may include kidney problems, lactic acidosis, and liver problems. It is crucial to monitor for side effects and consult a healthcare provider if they occur.

Drug Interactions

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide can interact with other medications, which can either diminish its effectiveness or increase the risk of side effects. It is important to inform healthcare providers of all medications being taken, including over-the-counter drugs and supplements.

Conclusion

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide represents a significant advancement in the management of HIV/AIDS, offering patients a convenient, once-daily regimen that can help achieve and maintain viral suppression. As with any medication, adherence to the prescribed regimen and regular monitoring by healthcare professionals are essential for its success.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian